🌟 Servier India Private Limited has launched its first oncology treatment. On the strength of its 38-year commitment to cardiovascular and metabolic diseases in India, the Group has taken a major step forward in its drive to be a focused and innovative player in oncology. Dr Poonam Gupta, our Medical and Patient Affairs Director, emphasizes our mission: 🗣️ “we are dedicated to developing innovative treatments that address unmet medical needs, deliver personalized and targeted care, and empower both healthcare professionals and patients.” Launching this treatment in India is directly in line with our #Servier2030 ambition of being a leading and innovative player in the treatment of rare cancers. Over 70% of the overall 🔬 R&D budget is allocated to research into cancer treatments. 👉 Learn more about our commitment 🔗 https://lnkd.in/gY-TzPpe #Oncology #Cancer #WeAreServier #MovedByYou
Servier
Fabrication de produits pharmaceutiques
Committed to therapeutic progress to serve patient needs
À propos
Fondé pour servir la santé, Servier est un groupe pharmaceutique international gouverné par une Fondation, qui aspire à avoir un impact sociétal significatif pour les patients et pour un monde durable. Son modèle unique de gouvernance lui permet de servir pleinement sa vocation avec une vision à long terme : être engagé pour le progrès thérapeutique au bénéfice des patients. Les 21 900 collaborateurs qui composent le Groupe sont engagés autour de cette vocation commune, source d’inspiration au quotidien. Leader mondial en cardiologie, Servier a pour ambition de devenir un acteur focalisé et innovant en oncologie en ciblant des cancers difficiles à traiter. C’est pourquoi le Groupe consacre plus de 70 % de son budget de R&D au développement de thérapies ciblées et innovantes en oncologie. Les neurosciences et les maladies immuno-inflammatoires constituent un futur relais de croissance. Dans ces domaines, Servier se focalise sur un nombre restreint de pathologies spécifiques dans lesquelles une caractérisation précise des patients permet de proposer une réponse thérapeutique ciblée, grâce à la médecine de précision. Pour favoriser l’accès à des soins de qualité pour tous, et à moindre coût, le Groupe propose également une offre de médicaments génériques couvrant la majorité des pathologies, en s’appuyant sur des marques fortes en France, en Europe de l’Est, au Brésil et au Nigeria. Dans tous ces domaines, le Groupe intègre la voix du patient à chaque étape du cycle de vie du médicament. Servier, dont le siège social est basé en France, s’appuie sur une solide implantation géographique dans plus de 150 pays et a réalisé, en 2023, un chiffre d’affaires de 5,3 milliards d’euros. --- Si vous avez constaté ou si vous pensez être sujet à un problème de santé lié à l’utilisation d’un médicament Servier ou de tout autre produit de santé Servier, rendez-vous sur servier.com
- Site web
-
https://servier.com
Lien externe pour Servier
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- + de 10 000 employés
- Siège social
- Suresnes
- Type
- Société civile/Société commerciale/Autres types de sociétés
Lieux
-
Principal
Obtenir l’itinéraire
50 rue Carnot
92150 Suresnes, FR
Employés chez Servier
Nouvelles
-
🧑🔬 The 1970s were pivotal for Kendall Square Association, establishing it as a hub for scientific innovation. Massachusetts Institute of Technology researchers made groundbreaking advances, and the area saw the birth of pioneering biotech companies. 💡This decade also introduced an “academic entrepreneur” culture, where research was directed toward practical, patient-focused solutions. 🤝 Kendall Square's unique environment began to attract top scientists and new biotech startups, creating a thriving ecosystem for innovation. To learn more about the history of Kendall Square, read the article in our latest issue of Insights by Servier 👉 https://bit.ly/3N2DxAw #WeAreServier #innovation #InsightsByServier
Ce contenu n’est pas disponible ici
Accédez à ce contenu et plus encore dans l’application LinkedIn
-
💪 2024 marks the start of a third year of our collaboration with Aitia, the market leader for digital twins and causal AI technology. Together, we are developing “Gemini” digital twins with a view to identifying new therapeutic targets for pancreatic cancer, Parkinson’s disease and now glioma. 👨💻 By combining our scientific expertise with Aitia's advanced technology, we are paving the way for more personalized and effective treatments for patients. This collaboration highlights the importance of innovation in healthcare and our commitment to improving patient outcomes. Hear from Fabien Schmidlin, Executive Director of Translational Medicine, R&D at Servier, who looks at how this technology can contribute to research and its application for the health sector 👉 https://lnkd.in/eHBjYyBB #Healthcare #Innovation #DigitalTwins #Collaboration
-
-
🗓️ November is #GastricCancerAwarenessMonth, the perfect moment to raise awareness of one of the world’s most widespread cancers. 📊 Gastric cancer is the 5th most common cancer globally, with over 1 million new cases diagnosed annually. Despite its prevalence, many remain unaware of its symptoms and risk factors, which can delay early diagnosis and care. 💪 At Servier, we are committed to enhancing awareness and education on gastric cancer. By providing resources and information, we aim to support healthcare professionals in identifying and addressing risk factors early, ultimately improving patient outcomes. Learn more about our commitment to gastric cancer awareness and education 👉 https://lnkd.in/eSHtQxvQ #WeAreServier #Oncology #CancerAwareness
-
Education for a better adherence Informing patients is a key factor for a better response to treatment. This approach can improve the management of chronic diseases by enhancing adherence to drugs or lifestyle modifications. 💊💪 According to Dr. Arun Sharma, MD MBA, an MD at Servier, “When you empower patients with knowledge and give them the right tools to understand their hypertension much better, they can be coaches of their own lives.” For more information, visit servier.com 👉 https://bit.ly/3E7s4Lj #YouAreTheCoach #TakeYourMedicine 💪 #BecauseIsayso
-
🌍 We are pleased to announce our participation in BIO-Europe, taking place from November 4th to 6th in Sweden. 2024 marks BIO-Europe's 30 years of facilitating partnerships. Join us on Tuesday, November 5th, from 11:45 AM to 12:00 PM! Anne Dagallier, Director of Business Development Global Lead Oncology at Servier, will present our Group and share our strategy and ambition for 2030.. Our Global Business Development teams will be available to meet with you. See you in Sweden! 🇸🇪 #BIOEurope #oncology #innovation #healthcare
-
-
🚨The application period for the Servier Golden Ticket is open! Want to make your application stand out? Here’s how to leverage the FREE one-year residency at Spartners by Servier & BioLabs France: 1️⃣ Highlight Your Innovation’s Impact 2️⃣ Showcase How You’ll Utilize the Workspace 3️⃣ Demonstrate Readiness for Expert Mentorship 4️⃣ Detail Your Goals and Milestones 5️⃣ Ensure a Polished and Complete Application Apply by December 1st for a chance to win all these benefits! Apply here 👉 https://lnkd.in/eJPwvxSN #incubator #biotech #innovation
Reminder - The application period for the Servier Golden Ticket is open until December 1st. Win a #FREE one-year residency at Spartners with: ✅ A dedicated lab bench and membership ✅ Exclusive use of state-of-the-art facilities and equipment ✅ Direct engagement with Servier’s team of scientific and industrial advisors ✅ BioLabs dedicated team and International Network Ready to take your innovation to the next level? Here’s how you can secure your place: #Step1: Submit your online application by December 1st. #Step2: By January 9, 2025, our expert panel will shortlist a group of finalists. #Step3: On January 23, 2025, finalist startups will present their innovative companies and scientific concepts during the Golden Ticket Award Ceremony. #Step4: The coveted award will be granted as detailed above. Good luck to all applicants – we can’t wait to see what you’ll bring to the table! 👇 Apply below December 1st and unlock these advantages! https://lnkd.in/eJPwvxSN Johanna Michielin, Hélène Sire, Anais Ralimbimanana, Jean-Roch Llense, Marianna Karampournioti Sotti, Chaimaa Asri, Celine Triquel, Laura Dupuy
-
-
🎥 Watch the testimonials of Cécile Pradeau, head of Partnerships at Planète Urgence, and Elodie BORGES 💫, Project Manager in Corporate Philanthropy - Mécénat Servier. They share how Congé Solidaire® transforms employees into true agents of change, while offering them an unforgettable human and cultural experience. 💚 👇 For the full interview: 👉 https://lnkd.in/esF-mTAy
📣 Depuis 2000, Planète Urgence noue des partenariats avec des entreprises et des collectivités qui souhaitent avoir un impact durable sur l’environnement et contribuer à un monde plus solidaire. 🌳 Grâce à notre dispositif unique, le Congé Solidaire®, nous proposons aux entreprises l'opportunité d'engager leurs collaborateurs dans des missions de volontariat international pendant leurs congés, en apportant leurs compétences à des organisations locales au service de la forêt. 🤝 Depuis 2017, le Fonds de Dotation Mécénat Servier, partenaire historique de Planète Urgence, permet à ses salariés du monde entier de saisir cette opportunité. Ils partent sur le terrain vivre une expérience transformative aux bénéfices d'organisations locales ayant des besoins spécifiques d'accompagnement. 🔎 Mais en quoi ce type de partenariat est-il si bénéfique ? Quels avantages apporte-t-il aux collaborateurs, à l’entreprise et à la société dans son ensemble ? 🎥 Découvrez le témoignage Cécile Pradeau, Responsable Partenariats Entreprises chez Planète Urgence, et Elodie BORGES 💫, Chef de Projets Mécénat pour le Fonds de Dotation Mécénat Servier. Elles partagent comment le Congé Solidaire® transforme les collaborateurs en véritables acteurs du changement, tout en leur offrant une expérience humaine et culturelle inoubliable. 💚 Pour découvrir l’interview complète : 👉 https://lnkd.in/eG39b5Jd Un grand merci à Wenabi pour la réalisation de cette vidéo #BestPartnersEver ! 👏 #PlaneteUrgence #Servier #CongéSolidaire #engagement #environnement
-
📍 Kendall Square Association, part of the Boston-Cambridge area, boasts the highest concentration of scientific talent globally. Since Massachusetts Institute of Technology's expansion in 1916, it has transformed into a leading biotechnology hub. Key milestones include groundbreaking DNA research in the 1970s and the development of the first recombinant DNA research by Biogen in the 1980s. Today, it hosts over 1,000 companies and top universities, driving increasing innovation. 💡 Strategically located between MIT and Harvard University, Kendall Square's vibrant ecosystem of biotechs, pharma giants and research institutions fosters groundbreaking scientific discoveries. Find the full article in our latest issue of Insights by Servier 👉 https://bit.ly/3N2DxAw #WeAreServier #innovation #InsightsByServier
-
Every patient is unique, and various factors can impact adherence to chronic disease treatments. Tailor the treatment Do your patients often forget to take their numerous pills? 💊 Daily use of single-pill combinations was shown to be consistently associated with better adherence and disease control. Dr. Arun Sharma, MD MBA, an MD at Servier, explains in this video how tailoring the regimen can improve patient outcomes and adherence. For more information, visit servier.com 👉 https://bit.ly/3u1LLme #YouAreTheCoach #TakeYourMedicine 💪 #BecauseIsayso